bioAffinity Technologies, Inc.
BIAF
$0.83
-$0.01-1.23%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 5.66M | 6.16M | 6.78M | 7.68M | 8.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.66M | 6.16M | 6.78M | 7.68M | 8.81M |
| Cost of Revenue | 3.79M | 4.23M | 4.89M | 5.39M | 5.78M |
| Gross Profit | 1.87M | 1.94M | 1.89M | 2.29M | 3.03M |
| SG&A Expenses | 10.70M | 9.91M | 9.80M | 9.95M | 10.21M |
| Depreciation & Amortization | 464.80K | 504.90K | 534.80K | 572.70K | 610.60K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.22M | 16.73M | 17.16M | 17.74M | 18.44M |
| Operating Income | -11.56M | -10.57M | -10.38M | -10.06M | -9.64M |
| Income Before Tax | -15.84M | -14.87M | -14.70M | -11.65M | -9.72M |
| Income Tax Expenses | 35.40K | 44.10K | 40.90K | 40.30K | 16.70K |
| Earnings from Continuing Operations | -15.88 | -14.91 | -14.74 | -11.69 | -9.74 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.88M | -14.91M | -14.74M | -11.69M | -9.74M |
| EBIT | -11.56M | -10.57M | -10.38M | -10.06M | -9.64M |
| EBITDA | -13.40M | -12.37M | -12.15M | -11.80M | -10.87M |
| EPS Basic | -11.32 | -15.42 | -20.73 | -20.84 | -21.33 |
| Normalized Basic EPS | -7.05 | -9.60 | -12.92 | -12.99 | -13.31 |
| EPS Diluted | -11.32 | -15.42 | -20.73 | -20.84 | -21.33 |
| Normalized Diluted EPS | -7.05 | -9.60 | -12.92 | -12.99 | -13.31 |
| Average Basic Shares Outstanding | 10.83M | 6.88M | 2.90M | 2.25M | 1.83M |
| Average Diluted Shares Outstanding | 10.83M | 6.88M | 2.90M | 2.25M | 1.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |